Stifel initiated coverage of Eupraxia Pharmaceuticals (NasdaqCM:EPRX) with a Buy recommendation on May 21, 2026. The average one-year price target is projected at $12.09 per share, indicating an upside of 89.83% from its latest closing price of $6.37 per share.
Eupraxia’s projected annual revenue is $46 million, with a projected annual non-GAAP EPS of -$0.54. Institutional interest has risen significantly, with 57 funds reporting positions, a 50% increase over the last quarter, and total shares owned by institutions up 63.47% to 21,985,000 shares.
Notable shareholders include Beutel, Goodman & Co. with 3,666,000 shares (5.96% ownership), and Affinity Asset Advisors, which increased its holdings from 300,000 to 1,589,000 shares (2.58% ownership), reflecting an 81.12% increase.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
